Gilead says U.S. FDA could expand remdesivir use despite mixed data

ad+1

Shares of Gilead rose 45 cents to close at $66.50 Friday on the Nasdaq exchange


from Report on Business - The Globe and Mail
Read The Rest:theglobeandmail...

0 comments: